ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / NSPR / earnings
PMI (48) RVP (31) PLRZ (34) MODD (33) ⌘ Pro Terminal →

InspireMD Inc. (NSPR) Next Earnings Date & Expected ±12.5% Move

$0.45 -0.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.45

InspireMD Inc. (NSPR) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $20.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NSPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, InspireMD Inc. (NASDAQ: NSPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.45 (-0.31% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #735 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NSPR compare to PMI and RVP in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PMI (Picard Medical Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $20.5M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NSPR?
▼

Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.45 (-0.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (6)SEC (8)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
$3 Bull$0 Base$0 Bear
📬 FREE NSPR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NSPR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY NSPR SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 30.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$0.50-12% Next Q
Q2 (-2Q)
37
Grade E$0.44+4.5% Next Q
Q3 (-1Q)
35
Grade E$0.46-2.2% Next Q
Current
32
Grade E$0.45-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NSPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NSPR currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.47) forces dealer call-delta covering toward $2.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.06 Expected Swing
$1.00 (-12.5%)Spot $0.45$0.51 (+12.5%)
MODEL EARNINGS SETUP GAUGE

NSPR Quantitative Pre-Earnings Setup: 32/100

Trailing EPS: $4.25 • YoY Revenue Growth: 28.1%

Model Bullish Setup (32/100)Model Risk Weight (68/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$9.0M-$48.8M-$36.8M29.5%
FY 20242024-12-31$7.0M-$32.0M-$23.3M21.5%
FY 20232023-12-31$6.2M-$19.9M-$16.4M29.5%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NSPR)

  • ✓Walkthrough of NSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.54%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.45H $0.45L $0.45C $0.45VOL 478.7K
RES: $0.79SUP: $0.42SMA50: $0.65SMA200: $1.06
$2.09$1.64$1.19$0.74$0.29RES $0.79SUP $0.42$0.452026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NSPR Butterfly Map → + Track NSPR →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +28.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NSPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NSPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NSPR)

Health Care Rank #735 of 1016 ⚔️ PMI vs NSPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NSPR vs. PMI, RVP, PLRZ, MODD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InspireMD Inc. (NSPR) ranks #735 by composite RQD confidence (32/100, grade E) and #827 by equity capitalization ($20.9M). Within this direct 5-issuer industry benchmark cohort, NSPR leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NSPR at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NSPR ACTIVE
InspireMD Inc.
E 32/100 — 29.5% -35.0% -0.31% $20.9M Benchmark Subject
PMI
Picard Medical Inc.
D 48/100 — — — +2.96% $20.5M /pmi-vs-nspr →
RVP
Retractable Technologies Inc.
E 31/100 — 0.1% -23.3% -1.96% $16.9M /rvp-vs-nspr →
PLRZ
Polyrizon Ltd.
E 34/100 — — -25.1% +19.40% $26.1M /plrz-vs-nspr →
MODD
Modular Medical Inc.
E 33/100 — — -35.0% 0.00% $16.3M /modd-vs-nspr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001433607

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InspireMD Inc. (NSPR) reported GAAP revenue of $9.0M (+28.1% vs. FY2024 revenue of $7.0M , and +44.7% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$35.1M, and free cash flow of -$36.8M (-58.0% YoY). On the balance sheet, NSPR closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.0M -$48.8M -$35.1M -$36.8M $69.4M —
FY2024 (FY) 2024-12-31 $7.0M -$32.0M -$21.9M -$23.3M $46.8M —
FY2023 (FY) 2023-12-31 $6.2M -$19.9M -$16.4M -$16.4M — —

3. NSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, InspireMD Inc. (NASDAQ: NSPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.45 (-0.31% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #735 in composite RQD confidence.

How does NSPR compare to PMI and RVP in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PMI (Picard Medical Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $20.5M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NSPR?

Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NSPR trading relative to its 50-day, 200-day, and 52-week technical levels?

NSPR last traded at $0.45 (-0.31% on volume of 478,664 shares), positioning the stock -30.77% below its 50-day simple moving average ($0.65) and -57.55% below its 200-day simple moving average ($1.06). Across its 52-week range of $0.43 to $2.40, NSPR sits at the 1.0% percentile with a 14-day RSI of 30.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.51).

NSPR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is NSPR's next earnings date?

Based on SEC filing cadence, InspireMD Inc. (NSPR)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is NSPR stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for NSPR, spanning a range between $1 and $0.51.

Direct Sub-Reports: NSPR RQD Cockpit NSPR 12M Forecast NSPR Earnings & Move NSPR Dividends & DRIP NSPR Insiders & 13F NSPR Whale Options NSPR Profit Sankey NSPR News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NSPR — InspireMD Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:49:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, NSPR scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

  • Fundamental Cash Engine: 6 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%, meaning the business is not currently generating returns on capital or free cash flow to shareholders.
  • Whale 13F Flow: 6 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The score is weak, indicating limited institutional conviction in the source data.
  • Insider Conviction: 5 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scored low, the weakest of the five pillars.
  • Macro Regime Fit: 7 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. The pillar offers little regime-based support.
  • Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 4/9, and Debt/Equity is 0.5. These are the strongest readings but still fall in the lower range of the scale.

Implications for a prospective investor evaluating the stock today: the rating points to weak cash generation, low institutional and insider conviction, and forensic caution. Any upside case would need to rest on a turnaround in operating economics, which the source data does not show. The valuation context is a $0.45 share price against a $21.0M market cap, with the stock trading in a $0.43 – $2.4 range over 52 weeks. The price sits near the bottom of that range, which reflects the deterioration captured by the RQD pillars rather than a signal of undervaluation on its own.

Business

InspireMD Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, it is a Health Care issuer operating in Medical/Dental Instruments. The source data does not describe its specific products, customers, or detailed revenue model. Revenue is reported in the financials at $9.0M for FY 2025.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$9.0M$-49.6M$-48.8MN/A$-36.8M$8.9MN/A
FY 2024$7.0M$-33.5M$-32.0MN/A$-23.3M$18.9MN/A
FY 2023$6.2M$-21.1M$-19.9MN/A$-16.4MN/AN/A

Per the SEC financials, revenue rose from $6.2M in FY 2023 to $9.0M in FY 2025, while operating losses widened from $-21.1M to $-49.6M over the same span. Per the market data, gross margin is 29.5%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9. Per the SEC financials, cash declined from $18.9M in FY 2024 to $8.9M in FY 2025, and debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most recent items are market-wire coverage. Headlines include a Benzinga pre-market report that mentions NSPR among health care movers, an announcement that InspireMD will report third quarter 2026 financial results, a technical-level report noting the stock climbing 8.5% to $0.52 and reclaiming the $0.50 level, and two Traders Union stock and technical analysis pages. Each item is marked YELLOW in the source and categorized as MARKET WIRE. The source does not provide substantive detail on the content of the third quarter 2026 results announcement. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is the Health Care / Medical/Dental Instruments classification and the Roarable RQD beta reading of 1.0.

Analyst View & Smart Money Ownership

Per the analyst data section: NONE. Consensus rating and price targets are not available in source data.

Per the holders section: NONE. Insider Form 4, 13F whale, and Congressional trade details are not available in source data.

Open Questions

  • What is the company's specific product portfolio, customer base, and revenue mix behind the reported $9.0M FY 2025 revenue?
  • What is total debt, given that the financials report debt as N/A while the RQD rating cites Debt/Equity of 0.5?
  • What drove the reported operating loss of $-49.6M in FY 2025, and what is the path to positive operating income?
  • What are the contents and results of the announced third quarter 2026 financial report?
  • What is the company's cash runway given $8.9M in cash against a $-36.8M FCF in FY 2025?

NSPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InspireMD Inc. (NSPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NSPR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NSPR Bull vs. Bear Conversation Board — What's Your Call at $0.45?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NSPR 🐻 67% BEARISH CONVICTION
1. Pick Your Side on NSPR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.40 (-11.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NSPR (E • RQD 32/100) a Buy at $0.45?

Welcome to the NSPR (InspireMD Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.38 (-15.6%)
Spot @ $0.45

Pump the brakes on NSPR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NSPR, but look at what you are paying: current EV/EBITDA multiples with 29.5% gross margins. Unless InspireMD Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.56 (+24.4%)
Spot @ $0.45

NSPR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NSPR, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.45 (52-wk range $0.43 - $2.40), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%